{"prompt": "['Death', 'Life-threatening (Note: The term \"life-threatening\" in the definition of \"serious\" refers to an', 'event in which the subject was at risk of death at the time of the event; it does not refer to an', 'event that hypothetically might have caused death if it were more severe.)', 'In-patient hospitalization or prolongation of existing hospitalization', 'Persistent or significant disability/incapacity', 'A congenital anomaly/birth defect', 'A medically important event or reaction: such events may not be immediately life-threatening or', 'result in death or hospitalization but may jeopardize the subject or may require intervention to', 'prevent one of the other outcomes constituting SAEs. Medical and scientific judgment must be', 'exercised to determine whether such an event is a reportable under expedited reporting rules.', 'Examples of medically important events include intensive treatment in an emergency room or at', 'home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in', 'hospitalization; and development of drug dependency or drug abuse. For the avoidance of', 'doubt, infections resulting from contaminated medicinal product will be considered a medically', 'important event and subject to expedited reporting requirements.', 'Clarification of Serious Adverse Events:', 'Death is an outcome of an adverse event, and not an adverse event in itself. In reports of death', 'due to \"Disease Progression\", where no other information is provided, the death will be', 'assumed to have resulted from progression of the disease being treated with the study drugs.', 'All deaths, regardless of cause, must be reported for subjects on study and for deaths occurring', 'within 30 days of the last study evaluation.', '\"Occurring at any dose\" does not imply that the subject is receiving study drug at the time of the', 'event. Dosing may have been given as treatment cycles or interrupted temporarily prior to the', 'onset of the SAE, but may have contributed to the event.', '\"Life-threatening\" means that the subject is at immediate risk of death from the event as it', 'occurred. This does not include an event that might have led to death, if it had occurred with', 'greater severity.', \"Complications that occur during hospitalizations are AE's. If a complication prolongs\", 'hospitalization, it is an SAE.', '\"Inpatient hospitalization\" means the subject has been formally admitted to a hospital for', 'medical reasons, for any length of time. This may or may not be overnight. It does not include', 'presentation and care within an emergency department.', 'The Investigator should attempt to establish a diagnosis of the event based on signs, symptoms', 'and/or other clinical information. In such cases, the diagnosis should be documented as the AE', 'and/or SAE and not the individual signs/symptoms', 'NOTE: The following hospitalizations are not considered SAEs:', 'A visit to the emergency room or other hospital department lasting less than 24 hours that does', 'not result in admission (unless considered an \"important medical event\" or a life-threatening', 'event)', 'Elective surgery planned before signing consent', 'Admissions as per protocol for a planned medical/surgical procedure', 'Routine health assessment requiring admission for baseline/trending of health status (e.g.,', 'routine colonoscopy)', 'CRI 15-05 Protocol 13SEP2017', 'Page 31']['Medical/surgical admission for purpose other than remedying ill health state that was planned', 'before study entry. Appropriate documentation is required in these cases.', 'Admission encountered for another life circumstance that carries no bearing on health status', 'and requires no medical/surgical intervention (e.g., lack of housing, economic inadequacy,', 'caregiver respite, family circumstances, administrative).', '9.1.3', 'Clinical Laboratory Abnormalities and Other Abnormal Assessments as Adverse Events or Serious', 'Adverse Events', 'Laboratory abnormalities without clinical significance are not recorded as AEs or SAEs. However,', 'laboratory abnormalities (e.g., clinical chemistry, hematology, and urinalysis) that require medical or', 'surgical intervention or lead to study drug interruption, modification, or discontinuation must be', 'recorded as an AE, as well as an SAE, if applicable. In addition, laboratory or other abnormal assessments', '(e.g., electrocardiogram, x-rays, vital signs) that are associated with signs and/or symptoms must be', 'recorded as an AE or SAE if they meet the definition of an AE or SAE as described in Sections 9.1.1 and', '9.1.2 If the laboratory abnormality is part of a syndrome, record the syndrome or diagnosis (e.g.,', 'anemia), not the laboratory result (i.e., decreased hemoglobin).', 'For specific information on handling of clinical laboratory abnormalities in this study, please refer to', 'Section 9.5.', '9.2 Assessment of Adverse Events and Serious Adverse Events', 'The Investigator or qualified Sub-Investigator is responsible for assessing AEs and SAEs for causality and', 'severity, and for final review and confirmation of accuracy of event information and assessments.', '9.2.1 Assessment of Causality for Study Drugs and Procedures', 'The Investigator or qualified Sub-Investigator is responsible for assessing the relationship to study drug', 'treatment using clinical judgment and the following considerations:', 'No: Evidence exists that the adverse event has an etiology other than the study drug. For SAEs,', 'an alternative causality must be provided (e.g., pre-existing condition, underlying disease,', 'intercurrent illness, or concomitant medication).', 'Yes: There is reasonable possibility that the event may have been caused by the investigational', 'medicinal product.', 'It should be emphasized that ineffective treatment should not be considered as causally related in the', 'context of adverse event reporting.', 'The relationship to study procedures (e.g., invasive procedures such as venipuncture or biopsy) should', 'be assessed using the following considerations:', 'No: Evidence exists that the adverse event has an etiology other than the study procedure.', 'Yes: The adverse event occurred as a result of protocol procedures, (e.g., venipuncture)', '9.2.2 Assessment of Severity', 'The severity grading of AEs will be assessed as Grade 1, 2, 3, or 4 using the GSI Grading Scale for Severity', 'of Adverse Events and Laboratory Abnormalities (Appendix 4).', 'For AEs associated with laboratory abnormalities, the event should be graded on the basis of the clinical', 'severity in the context of the underlying conditions; this may or may not be in agreement with the', 'grading of the laboratory abnormality.', 'CRI 15-05 Protocol 13SEP2017', 'Page 32']\n\n###\n\n", "completion": "END"}